Balance Sheet

Cash Flow Statement

Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Divestments (2019 - 2023)

Legend Biotech filings provide 5 years of Divestments readings, the most recent being $407.5 million for Q4 2023.

On a quarterly basis, Divestments rose 1534.48% to $407.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $590.1 million, a 99.32% increase, with the full-year FY2023 number at $92.8 million, up 220.36% from a year prior.
Divestments hit $407.5 million in Q4 2023 for Legend Biotech, up from $24.9 million in the prior quarter.
In the past five years, Divestments ranged from a high of $407.5 million in Q4 2023 to a low of $24.9 million in Q4 2022.
Median Divestments over the past 5 years was $96.5 million (2021), compared with a mean of $140.7 million.
Biggest five-year swings in Divestments: tumbled 74.17% in 2022 and later skyrocketed 1534.48% in 2023.
Legend Biotech's Divestments stood at $113.5 million in 2019, then plummeted by 46.09% to $61.2 million in 2020, then skyrocketed by 57.79% to $96.5 million in 2021, then tumbled by 74.17% to $24.9 million in 2022, then skyrocketed by 1534.48% to $407.5 million in 2023.
The last three reported values for Divestments were $407.5 million (Q4 2023), $24.9 million (Q4 2022), and $96.5 million (Q4 2021) per Business Quant data.